22 B
- I
oxacalcitriol I
suppresses O
secondary O
hyperparathyroidism O
without O
inducing O
low O
bone O
turnover O
in O
dogs O
with O
renal O
failure O
. O

A O
new O
vitamin B
D I
analogue O
, O
22 B
- I
oxacalcitriol I
( O
OCT B
) O
, O
has O
been O
shown O
to O
have O
promising O
characteristics O
. O

On O
Day O
8 O
, O
the O
nerve O
- O
evoked O
peak O
twitch O
tensions O
, O
tetanic O
tensions O
, O
and O
fatigability O
, O
and O
the O
dose O
- O
response O
curves O
of O
d B
- I
tubocurarine I
in O
the O
tibialis O
cranialis O
muscle O
were O
measured O
in O
vivo O
and O
related O
to O
muscle O
mass O
or O
expression O
of O
AChRs O
. O

The O
50 O
% O
effective O
dose O
of O
d B
- I
tubocurarine I
( O
microg O
/ O
kg O
) O
in O
the O
tibialis O
muscle O
was O
smaller O
in O
the O
P10 O
( O
33 O
. O
6 O
+ O
/ O
- O
5 O
. O
4 O
) O
than O
in O
the O
S O
( O
61 O
. O
9 O
+ O
/ O
- O
5 O
. O
0 O
) O
or O
the O
P100 O
( O
71 O
. O
3 O
+ O
/ O
- O
9 O
. O
6 O
) O
groups O
. O

The O
50 O
% O
effective O
dose O
of O
d B
- I
tubocurarine I
did O
not O
correlate O
with O
muscle O
mass O
or O
AChR O
expression O
. O

The O
effects O
of O
N B
- I
nitro I
- I
L I
- I
arginine I
- I
methyl I
ester I
( O
L B
- I
NAME I
) O
a O
nitric B
oxide I
( O
NO B
) O
synthase O
inhibitor O
and O
L B
- I
arginine I
, O
a O
NO B
precursor O
, O
were O
investigated O
on O
lidocaine B
- O
induced O
convulsions O
. O

The O
effects O
of O
N B
- I
nitro I
- I
L I
- I
arginine I
- I
methyl I
ester I
( O
L B
- I
NAME I
) O
a O
nitric B
oxide I
( O
NO B
) O
synthase O
inhibitor O
and O
L B
- I
arginine I
, O
a O
NO B
precursor O
, O
were O
investigated O
on O
lidocaine B
- O
induced O
convulsions O
. O

In O
the O
first O
experiment O
, O
four O
groups O
of O
mice O
received O
physiological O
saline O
( O
0 O
. O
9 O
% O
) O
, O
L B
- I
arginine I
( O
300 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
L B
- I
NAME I
( O
100 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
diazepam B
( O
2 O
mg O
/ O
kg O
) O
, O
respectively O
. O

In O
the O
first O
experiment O
, O
four O
groups O
of O
mice O
received O
physiological O
saline O
( O
0 O
. O
9 O
% O
) O
, O
L B
- I
arginine I
( O
300 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
L B
- I
NAME I
( O
100 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
diazepam B
( O
2 O
mg O
/ O
kg O
) O
, O
respectively O
. O

L B
- I
NAME I
( O
100 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
diazepam B
( O
2 O
mg O
/ O
kg O
) O
significantly O
decreased O
the O
incidence O
of O
lidocaine B
( O
50 O
mg O
/ O
kg O
) O
- O
induced O
convulsions O
. O

In O
contrast O
, O
the O
L B
- I
arginine I
treatment O
increased O
the O
incidence O
of O
lidocaine B
( O
80 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
- O
induced O
convulsions O
significantly O
. O

OBJECTIVES O
: O
Recently O
published O
studies O
have O
demonstrated O
increased O
efficacy O
and O
cost O
- O
effectiveness O
of O
combination O
therapy O
with O
interferon O
and O
alpha O
- O
2b O
/ O
ribavirin B
compared O
with O
interferon B
- I
alpha I
monotherapy O
in O
the O
treatment O
of O
chronic O
hepatitis O
C O
( O
CHC O
) O
. O

Erectile O
function O
was O
assessed O
6 O
weeks O
following O
uni O
- O
and O
bilateral O
injections O
of O
6 B
- I
hydroxydopamine I
in O
the O
substantia O
nigra O
nucleus O
of O
the O
brain O
. O

Behavioral O
effects O
of O
MK B
- I
801 I
on O
reserpine B
- O
treated O
mice O
. O

The O
effects O
of O
dizocilpine B
( O
MK B
- I
801 I
) O
, O
a O
noncompetitive O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
antagonist O
, O
were O
studied O
on O
dopamine B
- O
related O
behaviors O
induced O
by O
reserpine B
treatments O
. O

MK B
- I
801 I
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
, O
administered O
30 O
min O
before O
the O
observation O
test O
, O
prevented O
the O
vacuous O
chewing O
movements O
, O
tongue O
protrusions O
and O
catalepsy O
induced O
by O
reserpine B
. O

However O
, O
MK B
- I
801 I
injection O
produced O
a O
significant O
increase O
of O
tremor O
in O
reserpine B
- O
treated O
mice O
. O

MK B
- I
801 I
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
administration O
attenuated O
the O
catalepsy O
and O
tremor O
induced O
by O
reserpine B
. O

Pretreatment O
with O
reserpine B
( O
1 O
mg O
/ O
kg O
) O
24 O
h O
before O
the O
observation O
test O
produced O
increases O
in O
vacuous O
chewing O
movements O
and O
tongue O
protrusion O
, O
as O
well O
as O
increases O
in O
tremor O
and O
catalepsy O
, O
whereas O
MK B
- I
801 I
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
injection O
90 O
min O
before O
the O
test O
reversed O
the O
effects O
of O
reserpine B
. O

Oral O
administration O
of O
lindane B
( O
2 O
. O
5 O
, O
5 O
, O
10 O
and O
15 O
mg O
/ O
kg O
, O
body O
weight O
) O
for O
5 O
days O
was O
found O
to O
produce O
a O
dose O
- O
dependent O
increase O
in O
the O
activity O
of O
P450 O
dependent O
7 O
- O
ethoxyresorufin O
- O
O O
- O
deethylase O
( O
EROD O
) O
, O
7 O
- O
pentoxyresorufin O
- O
O O
- O
dealkylase O
( O
PROD O
) O
and O
N B
- I
nitrosodimethylamine I
demethylase O
( O
NDMA B
- O
d O
) O
in O
rat O
brain O
and O
liver O
. O

Induction O
studies O
have O
further O
shown O
that O
while O
pretreatment O
of O
3 B
- I
methylcholanthrene I
( O
MC B
) O
, O
an O
inducer O
of O
P4501A1 O
/ O
1A2 O
, O
did O
not O
produce O
any O
significant O
effect O
in O
the O
incidence O
of O
lindane B
induced O
convulsions O
, O
pretreatment O
with O
phenobarbital B
( O
PB O
) O
, O
an O
inducer O
of O
P450 O
2B1 O
/ O
2B2 O
or O
ethanol B
, O
an O
inducer O
of O
P450 O
2E1 O
catalysed O
reactions O
, O
significantly O
increased O
the O
incidence O
of O
lindane B
induced O
convulsions O
. O

OBJECTIVE O
: O
To O
achieve O
absolute O
risk O
estimates O
of O
venous O
thromboembolism O
( O
VTE O
) O
among O
women O
on O
cyproterone B
acetate I
plus O
ethinylestradiol B
( O
CPA B
/ O
EE B
) O
, O
and O
among O
women O
on O
combined B
oral I
contraceptives I
( O
COCs B
) O
. O

The O
pressor O
responses O
and O
bradycardia O
to O
the O
alpha O
1 O
- O
agonist O
cirazoline B
( O
0 O
. O
6 O
and O
2 O
micrograms O
kg O
- O
1 O
i O
. O
v O
. O
) O
, O
the O
alpha O
2 O
- O
agonist O
Abbott B
- I
53693 I
( O
1 O
and O
3 O
micrograms O
kg O
- O
1 O
i O
. O
v O
. O
) O
, O
and O
noradrenaline B
( O
0 O
. O
1 O
and O
1 O
. O
0 O
micrograms O
kg O
- O
1 O
i O
. O
v O
. O
) O
were O
determined O
in O
conscious O
SHR O
with O
and O
without O
chronic O
prazosin B
pretreatment O
. O

On O
the O
other O
hand O
, O
the O
pressor O
effects O
of O
Abbott B
- I
53693 I
were O
similar O
in O
both O
groups O
of O
SHR O
, O
but O
the O
accompanying O
bradycardia O
was O
greater O
in O
SHR O
with O
chronic O
prazosin B
treatment O
than O
without O
such O
treatment O
. O

RESULTS O
: O
After O
adjustment O
for O
cardiovascular O
disease O
risk O
factors O
, O
type O
of O
diabetes O
medication O
used O
, O
duration O
of O
diabetes O
, O
and O
intakes O
of O
folate B
, O
vitamin B
E I
, O
and O
beta B
- I
carotene I
, O
the O
adjusted O
relative O
risks O
of O
total O
cardiovascular O
disease O
mortality O
were O
1 O
. O
0 O
, O
0 O
. O
97 O
, O
1 O
. O
11 O
, O
1 O
. O
47 O
, O
and O
1 O
. O
84 O
( O
P O
for O
trend O
< O
0 O
. O
01 O
) O
across O
quintiles O
of O
total O
vitamin B
C I
intake O
from O
food O
and O
supplements O
. O

Second O
, O
we O
investigated O
the O
effect O
of O
IT O
MK B
- I
801 I
( O
30 O
mug O
) O
on O
the O
histopathologic O
changes O
in O
the O
spinal O
cord O
after O
morphine B
- O
induced O
spastic O
paraparesis O
. O

IT O
MK B
- I
801 I
significantly O
reduced O
the O
number O
of O
dark O
- O
stained O
alpha O
- O
motoneurons O
after O
morphine B
- O
induced O
spastic O
paraparesis O
compared O
with O
the O
saline O
group O
. O

Dexrazoxane B
( O
ICRF B
- I
187 I
) O
is O
recommended O
for O
protection O
against O
anthracycline B
- O
induced O
cardiotoxicity O
. O

Although O
3 B
, I
4 I
- I
methylenedioxymethamphetamine I
( O
MDMA B
or O
ecstasy B
) O
has O
been O
shown O
to O
damage O
brain O
serotonin B
( O
5 B
- I
HT I
) O
neurons O
in O
animals O
and O
possibly O
humans O
, O
little O
is O
known O
about O
the O
long O
- O
term O
consequences O
of O
MDMA B
- O
induced O
5 B
- I
HT I
neurotoxic O
lesions O
on O
functions O
in O
which O
5 B
- I
HT I
is O
involved O
, O
such O
as O
cognitive O
function O
. O

Although O
3 B
, I
4 I
- I
methylenedioxymethamphetamine I
( O
MDMA B
or O
ecstasy B
) O
has O
been O
shown O
to O
damage O
brain O
serotonin B
( O
5 B
- I
HT I
) O
neurons O
in O
animals O
and O
possibly O
humans O
, O
little O
is O
known O
about O
the O
long O
- O
term O
consequences O
of O
MDMA B
- O
induced O
5 B
- I
HT I
neurotoxic O
lesions O
on O
functions O
in O
which O
5 B
- I
HT I
is O
involved O
, O
such O
as O
cognitive O
function O
. O

Although O
3 B
, I
4 I
- I
methylenedioxymethamphetamine I
( O
MDMA B
or O
ecstasy B
) O
has O
been O
shown O
to O
damage O
brain O
serotonin B
( O
5 B
- I
HT I
) O
neurons O
in O
animals O
and O
possibly O
humans O
, O
little O
is O
known O
about O
the O
long O
- O
term O
consequences O
of O
MDMA B
- O
induced O
5 B
- I
HT I
neurotoxic O
lesions O
on O
functions O
in O
which O
5 B
- I
HT I
is O
involved O
, O
such O
as O
cognitive O
function O
. O

Because O
5 B
- I
HT I
transporters O
play O
a O
key O
element O
in O
the O
regulation O
of O
synaptic O
5 B
- I
HT I
transmission O
it O
may O
be O
important O
to O
control O
for O
the O
potential O
covariance O
effect O
of O
a O
polymorphism O
in O
the O
5 B
- I
HT I
transporter O
promoter O
gene O
region O
( O
5 O
- O
HTTLPR O
) O
when O
studying O
the O
effects O
of O
MDMA B
as O
well O
as O
cognitive O
functioning O
. O

Because O
5 B
- I
HT I
transporters O
play O
a O
key O
element O
in O
the O
regulation O
of O
synaptic O
5 B
- I
HT I
transmission O
it O
may O
be O
important O
to O
control O
for O
the O
potential O
covariance O
effect O
of O
a O
polymorphism O
in O
the O
5 B
- I
HT I
transporter O
promoter O
gene O
region O
( O
5 O
- O
HTTLPR O
) O
when O
studying O
the O
effects O
of O
MDMA B
as O
well O
as O
cognitive O
functioning O
. O

Because O
5 B
- I
HT I
transporters O
play O
a O
key O
element O
in O
the O
regulation O
of O
synaptic O
5 B
- I
HT I
transmission O
it O
may O
be O
important O
to O
control O
for O
the O
potential O
covariance O
effect O
of O
a O
polymorphism O
in O
the O
5 B
- I
HT I
transporter O
promoter O
gene O
region O
( O
5 O
- O
HTTLPR O
) O
when O
studying O
the O
effects O
of O
MDMA B
as O
well O
as O
cognitive O
functioning O
. O

The O
protective O
role O
of O
mangiferin B
was O
analyzed O
by O
triphenyl B
tetrazolium I
chloride I
( O
TTC B
) O
test O
used O
for O
macroscopic O
enzyme O
mapping O
assay O
of O
the O
ischemic O
myocardium O
. O

Diagnostic O
markers O
such O
as O
N B
- I
terminal I
pro I
brain I
natriuretic I
peptide I
( O
NT B
- I
proBNP I
) O
or O
high O
- O
sensitive O
C O
- O
reactive O
protein O
might O
help O
in O
the O
early O
identification O
of O
patients O
at O
risk O
, O
thus O
avoiding O
the O
occurrence O
of O
serious O
cardiovascular O
toxicity O
. O

Effect O
of O
alpha B
- I
tocopherol I
and O
deferoxamine B
on O
methamphetamine B
- O
induced O
neurotoxicity O
. O

This O
study O
examined O
the O
effect O
of O
alpha B
- I
tocopherol I
( O
alpha B
- I
TC I
) O
, O
a O
scavenger O
of O
reactive O
oxygen B
species O
, O
and O
deferoxamine B
( O
DFO B
) O
, O
an O
iron B
chelator O
, O
on O
the O
MA B
- O
induced O
neurotoxicity O
. O

This O
study O
examined O
the O
effect O
of O
alpha B
- I
tocopherol I
( O
alpha B
- I
TC I
) O
, O
a O
scavenger O
of O
reactive O
oxygen B
species O
, O
and O
deferoxamine B
( O
DFO B
) O
, O
an O
iron B
chelator O
, O
on O
the O
MA B
- O
induced O
neurotoxicity O
. O

The O
rat O
received O
either O
alpha B
- I
TC I
( O
20 O
mg O
/ O
kg O
) O
intraperitoneally O
for O
3 O
days O
and O
30 O
min O
prior O
to O
MA B
administration O
or O
DFO B
( O
50 O
mg O
/ O
kg O
) O
subcutaneously O
30 O
min O
before O
MA B
administration O
. O

The O
concentrations O
of O
dopamine B
( O
DA B
) O
, O
serotonin B
and O
their O
metabolites O
decreased O
significantly O
after O
MA B
administration O
, O
which O
was O
inhibited O
by O
the O
alpha B
- I
TC I
and O
DFO B
pretreatment O
. O

alpha B
- I
TC I
and O
DFO B
attenuated O
the O
MA B
- O
induced O
hyperthermia O
as O
well O
as O
the O
alterations O
in O
the O
locomotor O
activity O
. O

These O
changes O
were O
significantly O
attenuated O
by O
alpha B
- I
TC I
and O
DFO B
. O

This O
suggests O
that O
alpha B
- I
TC I
and O
DFO B
ameliorate O
the O
MA B
- O
induced O
neuronal O
damage O
by O
decreasing O
the O
level O
of O
oxidative O
stress O
. O

The O
goal O
of O
this O
study O
was O
to O
assess O
the O
interactive O
effects O
of O
chronic O
anabolic O
androgenic O
steroid B
( O
AAS O
) O
exposure O
and O
brain O
serotonin B
( O
5 B
- I
hydroxytryptamine I
, O
5 B
- I
HT I
) O
depletion O
on O
behavior O
of O
pubertal O
male O
rats O
. O

The O
goal O
of O
this O
study O
was O
to O
assess O
the O
interactive O
effects O
of O
chronic O
anabolic O
androgenic O
steroid B
( O
AAS O
) O
exposure O
and O
brain O
serotonin B
( O
5 B
- I
hydroxytryptamine I
, O
5 B
- I
HT I
) O
depletion O
on O
behavior O
of O
pubertal O
male O
rats O
. O

Brain O
levels O
of O
5 B
- I
HT I
and O
its O
metabolite O
, O
5 B
- I
hydroxyindoleacetic I
acid I
( O
5 B
- I
HIAA I
) O
, O
were O
determined O
using O
HPLC O
. O

Brain O
levels O
of O
5 B
- I
HT I
and O
its O
metabolite O
, O
5 B
- I
hydroxyindoleacetic I
acid I
( O
5 B
- I
HIAA I
) O
, O
were O
determined O
using O
HPLC O
. O

PCPA B
significantly O
and O
substantially O
depleted O
5 B
- I
HT I
and O
5 B
- I
HIAA I
in O
all O
brain O
regions O
examined O
. O

PCPA B
significantly O
and O
substantially O
depleted O
5 B
- I
HT I
and O
5 B
- I
HIAA I
in O
all O
brain O
regions O
examined O
. O

Chronic O
T B
treatment O
significantly O
decreased O
5 B
- I
HT I
and O
5 B
- I
HIAA I
in O
certain O
brain O
areas O
, O
but O
to O
a O
much O
lesser O
extent O
than O
PCPA B
. O

Chronic O
T B
treatment O
significantly O
decreased O
5 B
- I
HT I
and O
5 B
- I
HIAA I
in O
certain O
brain O
areas O
, O
but O
to O
a O
much O
lesser O
extent O
than O
PCPA B
. O

Based O
on O
these O
data O
, O
it O
can O
be O
speculated O
that O
pubertal O
AAS O
users O
with O
low O
central O
5 B
- I
HT I
may O
be O
especially O
prone O
to O
exhibit O
aggressive O
behavior O
. O

RESULTS O
: O
We O
identified O
27 O
reports O
of O
toxic O
leukoencephalopathy O
in O
patients O
treated O
with O
methotrexate B
( O
intrathecal O
, O
systemic O
) O
, O
5 B
- I
fluorouracil I
and O
its O
derivative O
carmofur B
, O
and O
capecitabine B
. O

Blood O
samples O
for O
the O
analysis O
of O
plasma O
potassium B
, O
terbutaline B
, O
metoprolol B
( O
racemic O
, O
R O
- O
and O
S O
- O
isomer O
) O
, O
and O
alpha B
- I
hydroxymetoprolol I
concentrations O
were O
taken O
at O
regular O
time O
intervals O
, O
during O
8 O
hr O
after O
metoprolol B
. O

Higher O
metoprolol B
/ O
alpha B
- I
hydroxymetoprolol I
ratios O
in O
PMs O
were O
predictive O
for O
higher O
R O
- O
/ O
S O
- O
isomer O
ratios O
of O
unchanged O
drug O
. O

BACKGROUND O
: O
Unfractionated B
heparin I
sodium I
( O
UFH B
) O
or O
low B
- I
molecular I
weight I
heparin I
( O
LMWH O
) O
is O
used O
in O
anticoagulant O
protocols O
at O
several O
institutions O
to O
prevent O
thrombosis O
after O
liver O
transplantation O
. O

Using O
a O
mouse O
model O
, O
we O
tested O
whether O
the O
rapid O
reversal O
of O
anticoagulation O
using O
human O
prothrombin B
complex I
concentrate I
( O
PCC B
) O
can O
reduce O
hemorrhagic O
blood O
volume O
. O

Renal O
failure O
developed O
after O
a O
prolonged O
course O
of O
vancomycin B
therapy O
in O
2 O
patients O
who O
were O
receiving O
tenofovir B
disoproxil I
fumarate I
as O
part O
of O
an O
antiretroviral O
regimen O
. O

An O
activated O
moiety O
, O
i O
. O
e O
. O
N B
- I
acylimidazole I
derivative O
of O
etodolac B
( O
EAI B
) O
, O
was O
condensed O
with O
the O
polysaccharide O
polymer O
dextran B
of O
different O
molecular O
weights O
( O
40000 O
, O
60000 O
, O
110000 O
and O
200000 O
) O
. O

Moreover O
, O
M O
( O
3 O
) O
- O
muscarinic O
acetylcholine B
receptor O
( O
mAChR O
) O
antagonist O
4 B
- I
DAMP I
( O
4 B
- I
diphenylacetoxy I
- I
N I
- I
methylpiperidine I
- I
methiodide I
) O
partially O
abolished O
the O
beneficial O
effects O
of O
pilocarpine B
. O

Effect O
of O
Hibiscus B
rosa I
sinensis I
on O
reserpine B
- O
induced O
neurobehavioral O
and O
biochemical O
alterations O
in O
rats O
. O

Effect O
of O
methanolic O
extract O
of O
Hibiscus B
rosa I
sinensis I
( O
100 O
- O
300 O
mg O
/ O
kg O
) O
was O
studied O
on O
reserpine B
- O
induced O
orofacial O
dyskinesia O
and O
neurochemical O
alterations O
. O

Reserpine B
treated O
rats O
significantly O
developed O
vacuous O
chewing O
movements O
and O
tongue O
protrusions O
however O
, O
coadministration O
of O
Hibiscus B
rosa I
sinensis I
roots O
extract O
( O
100 O
, O
200 O
and O
300 O
mg O
/ O
kg O
, O
per O
orally O
) O
attenuated O
the O
effects O
. O

The O
results O
of O
the O
present O
study O
suggested O
that O
Hibiscus B
rosa I
sinensis I
had O
a O
protective O
role O
against O
reserpine B
- O
induced O
orofacial O
dyskinesia O
and O
oxidative O
stress O
. O

AMN082 B
( O
2 O
. O
5 O
and O
5 O
mg O
/ O
kg O
) O
reduces O
apomorphine B
- O
induced O
rotations O
in O
unilateral O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
- O
lesioned O
rats O
. O

AMN082 B
( O
2 O
. O
5 O
and O
5 O
mg O
/ O
kg O
) O
reduces O
apomorphine B
- O
induced O
rotations O
in O
unilateral O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
- O
lesioned O
rats O
. O

In O
a O
more O
complex O
task O
commonly O
used O
to O
evaluate O
major O
akinetic O
symptoms O
of O
PD O
patients O
, O
5 O
mg O
/ O
kg O
AMN082 B
reverses O
the O
increased O
reaction O
time O
to O
respond O
to O
a O
cue O
of O
bilateral O
6 B
- I
OHDA I
- O
lesioned O
rats O
. O

Glomerular O
filtration O
rate O
( O
GFR O
) O
and O
effective O
renal O
plasma O
flow O
( O
ERPF O
) O
were O
measured O
by O
inulin O
and O
para B
- I
aminohippurate I
( O
PAH B
) O
clearance O
, O
respectively O
. O

METHODS O
: O
Male O
Wistar O
rats O
received O
each O
dose O
of O
the O
alpha O
( O
2 O
) O
- O
adrenoceptor O
antagonist O
yohimbine B
( O
0 O
. O
25 O
- O
1 O
. O
0mg O
/ O
kg O
) O
, O
the O
5 B
- I
HT I
( O
2C O
) O
receptor O
agonist O
m B
- I
chlorophenylpiperazine I
( O
mCPP B
, O
0 O
. O
5 O
- O
2 O
. O
0mg O
/ O
kg O
) O
or O
the O
GABA B
( O
A O
) O
inverse O
receptor O
agonist O
pentylenetetrazole B
( O
PTZ B
, O
3 O
- O
30mg O
/ O
kg O
) O
and O
were O
subsequently O
tested O
in O
either O
LES O
or O
FPS O
. O

METHODS O
: O
Male O
Wistar O
rats O
received O
each O
dose O
of O
the O
alpha O
( O
2 O
) O
- O
adrenoceptor O
antagonist O
yohimbine B
( O
0 O
. O
25 O
- O
1 O
. O
0mg O
/ O
kg O
) O
, O
the O
5 B
- I
HT I
( O
2C O
) O
receptor O
agonist O
m B
- I
chlorophenylpiperazine I
( O
mCPP B
, O
0 O
. O
5 O
- O
2 O
. O
0mg O
/ O
kg O
) O
or O
the O
GABA B
( O
A O
) O
inverse O
receptor O
agonist O
pentylenetetrazole B
( O
PTZ B
, O
3 O
- O
30mg O
/ O
kg O
) O
and O
were O
subsequently O
tested O
in O
either O
LES O
or O
FPS O
. O

Coenzyme B
Q10 I
significantly O
reduced O
blood B
urea I
nitrogen I
and O
serum O
creatinine B
levels O
which O
were O
increased O
by O
cisplatin B
. O

Here O
we O
show O
that O
the O
recently O
reported O
ability O
of O
L B
- I
dihydroxyphenylalanine I
to O
reverse O
the O
protective O
effect O
of O
alpha B
- I
methyl I
- I
para I
- I
tyrosine I
on O
METH B
- O
induced O
DA B
neurotoxicity O
is O
also O
confounded O
by O
drug O
effects O
on O
body O
temperature O
. O

Haloperidol B
- O
induced O
catalepsy O
was O
challenged O
with O
prior O
intracollicular O
microinjections O
of O
glutamate B
NMDA B
receptor O
antagonists O
, O
MK B
- I
801 I
( O
15 O
or O
30 O
mmol O
/ O
0 O
. O
5 O
microl O
) O
and O
AP7 B
( O
10 O
or O
20 O
nmol O
/ O
0 O
. O
5 O
microl O
) O
, O
or O
of O
the O
NMDA B
receptor O
agonist O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
, O
20 O
or O
30 O
nmol O
/ O
0 O
. O
5 O
microl O
) O
. O

The O
results O
showed O
that O
intracollicular O
microinjection O
of O
MK B
- I
801 I
and O
AP7 B
previous O
to O
systemic O
injections O
of O
haloperidol B
significantly O
attenuated O
the O
catalepsy O
, O
as O
indicated O
by O
a O
reduced O
latency O
to O
step O
down O
from O
a O
horizontal O
bar O
. O

The O
serotonin B
6 O
( O
5 B
- I
HT6 I
) O
receptor O
is O
therapeutically O
targeted O
by O
several O
second O
generation O
antipsychotics O
, O
such O
as O
clozapine B
and O
olanzapine B
, O
and O
d B
- I
amphetamine I
- O
induced O
hyperactivity O
in O
rats O
is O
corrected O
with O
the O
use O
of O
a O
selective O
5 B
- I
HT6 I
receptor O
antagonist O
. O

The O
serotonin B
6 O
( O
5 B
- I
HT6 I
) O
receptor O
is O
therapeutically O
targeted O
by O
several O
second O
generation O
antipsychotics O
, O
such O
as O
clozapine B
and O
olanzapine B
, O
and O
d B
- I
amphetamine I
- O
induced O
hyperactivity O
in O
rats O
is O
corrected O
with O
the O
use O
of O
a O
selective O
5 B
- I
HT6 I
receptor O
antagonist O
. O

The O
serotonin B
6 O
( O
5 B
- I
HT6 I
) O
receptor O
is O
therapeutically O
targeted O
by O
several O
second O
generation O
antipsychotics O
, O
such O
as O
clozapine B
and O
olanzapine B
, O
and O
d B
- I
amphetamine I
- O
induced O
hyperactivity O
in O
rats O
is O
corrected O
with O
the O
use O
of O
a O
selective O
5 B
- I
HT6 I
receptor O
antagonist O
. O

In O
addition O
, O
the O
disrupted O
prepulse O
inhibition O
induced O
by O
d B
- I
amphetamine I
or O
phencyclidine B
was O
restored O
by O
5 B
- I
HT6 I
receptor O
antagonist O
in O
an O
animal O
study O
using O
rats O
. O

In O
addition O
, O
the O
disrupted O
prepulse O
inhibition O
induced O
by O
d B
- I
amphetamine I
or O
phencyclidine B
was O
restored O
by O
5 B
- I
HT6 I
receptor O
antagonist O
in O
an O
animal O
study O
using O
rats O
. O

These O
animal O
models O
were O
considered O
to O
reflect O
the O
positive O
symptoms O
of O
schizophrenia O
, O
and O
the O
above O
evidence O
suggests O
that O
altered O
5 B
- I
HT6 I
receptors O
are O
involved O
in O
the O
pathophysiology O
of O
psychotic O
disorders O
. O

Therefore O
, O
we O
conducted O
an O
analysis O
of O
the O
association O
of O
the O
5 B
- I
HT6 I
gene O
( O
HTR6 O
) O
with O
METH B
- O
induced O
psychosis O
. O

Neural O
correlates O
of O
S B
- I
ketamine I
induced O
psychosis O
during O
overt O
continuous O
verbal O
fluency O
. O

In O
a O
counterbalanced O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
study O
design O
, O
healthy O
subjects O
were O
administered O
a O
continuous O
subanesthetic O
S B
- I
ketamine I
infusion O
while O
differences O
in O
BOLD O
responses O
measured O
with O
fMRI O
were O
detected O
. O

Compound O
1 O
is O
a O
potent O
A O
( O
2A O
) O
/ O
A O
( O
1 O
) O
receptor O
antagonist O
in O
vitro O
( O
A O
( O
2A O
) O
K O
( O
i O
) O
= O
4 O
. O
1 O
nM O
; O
A O
( O
1 O
) O
K O
( O
i O
) O
= O
17 O
. O
0 O
nM O
) O
that O
has O
excellent O
activity O
, O
after O
oral O
administration O
, O
across O
a O
number O
of O
animal O
models O
of O
Parkinson O
' O
s O
disease O
including O
mouse O
and O
rat O
models O
of O
haloperidol B
- O
induced O
catalepsy O
, O
mouse O
model O
of O
reserpine B
- O
induced O
akinesia O
, O
rat O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
lesion O
model O
of O
drug O
- O
induced O

Compound O
1 O
is O
a O
potent O
A O
( O
2A O
) O
/ O
A O
( O
1 O
) O
receptor O
antagonist O
in O
vitro O
( O
A O
( O
2A O
) O
K O
( O
i O
) O
= O
4 O
. O
1 O
nM O
; O
A O
( O
1 O
) O
K O
( O
i O
) O
= O
17 O
. O
0 O
nM O
) O
that O
has O
excellent O
activity O
, O
after O
oral O
administration O
, O
across O
a O
number O
of O
animal O
models O
of O
Parkinson O
' O
s O
disease O
including O
mouse O
and O
rat O
models O
of O
haloperidol B
- O
induced O
catalepsy O
, O
mouse O
model O
of O
reserpine B
- O
induced O
akinesia O
, O
rat O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
lesion O
model O
of O
drug O
- O
induced O

EEG O
recordings O
were O
obtained O
before O
and O
15 O
minutes O
following O
penicillin B
- I
G I
injection O
, O
and O
at O
10th O
minutes O
following O
each O
stimulus O
for O
analysis O
in O
terms O
of O
frequency O
, O
amplitude O
, O
and O
power O
spectrum O
. O

Prostaglandin B
F2 I
alpha I
had O
little O
effect O
on O
pain O
responses O
. O

D B
- I
penicillamine I
in O
the O
treatment O
of O
localized O
scleroderma O
. O

Case O
reports O
of O
11 O
patients O
with O
severe O
, O
extensive O
localized O
scleroderma O
who O
were O
treated O
with O
D B
- I
penicillamine I
are O
summarized O
in O
this O
article O
. O

The O
dose O
of O
D B
- I
penicillamine I
associated O
with O
a O
favorable O
response O
was O
as O
low O
as O
2 O
to O
5 O
mg O
/ O
kg O
per O
day O
given O
over O
a O
period O
ranging O
from O
15 O
to O
53 O
months O
. O

D B
- I
Penicillamine I
caused O
nephrotic O
syndrome O
in O
1 O
patient O
and O
milder O
reversible O
proteinuria O
in O
3 O
other O
patients O
; O
none O
developed O
renal O
insufficiency O
. O

These O
data O
suggest O
that O
D B
- I
penicillamine I
may O
be O
effective O
in O
severe O
cases O
of O
localized O
scleroderma O
. O

Two O
elderly O
patients O
with O
a O
history O
of O
either O
cerebral O
vascular O
accident O
( O
CVA O
) O
or O
head O
trauma O
and O
no O
evidence O
of O
renal O
disease O
developed O
seizures O
while O
receiving O
maximum O
doses O
of O
imipenem B
/ I
cilastatin I
. O

Both O
patients O
had O
received O
maximum O
doses O
of O
other O
beta B
- I
lactam I
antibiotics O
without O
evidence O
of O
seizure O
activity O
. O

Although O
there O
have O
been O
anecdotal O
reports O
of O
cardiac O
toxicity O
associated O
with O
fluorouracil B
( O
5 B
- I
FU I
) O
therapy O
, O
this O
phenomenon O
has O
not O
been O
studied O
in O
a O
systematic O
fashion O
. O

We O
prospectively O
performed O
continuous O
ambulatory O
ECG O
monitoring O
on O
25 O
patients O
undergoing O
5 B
- I
FU I
infusion O
for O
treatment O
of O
solid O
tumors O
in O
order O
to O
assess O
the O
incidence O
of O
ischemic O
ST O
changes O
. O

Patients O
were O
monitored O
for O
23 O
+ O
/ O
- O
4 O
hours O
before O
5 B
- I
FU I
infusion O
, O
and O
98 O
+ O
/ O
- O
9 O
hours O
during O
5 B
- I
FU I
infusion O
. O

Patients O
were O
monitored O
for O
23 O
+ O
/ O
- O
4 O
hours O
before O
5 B
- I
FU I
infusion O
, O
and O
98 O
+ O
/ O
- O
9 O
hours O
during O
5 B
- I
FU I
infusion O
. O

Anginal O
episodes O
were O
rare O
: O
only O
one O
patient O
had O
angina O
( O
during O
5 B
- I
FU I
infusion O
) O
. O

However O
, O
asymptomatic O
ST O
changes O
( O
greater O
than O
or O
equal O
to O
1 O
mm O
ST O
deviation O
) O
were O
common O
: O
six O
of O
25 O
patients O
( O
24 O
% O
) O
had O
ST O
changes O
before O
5 B
- I
FU I
infusion O
v O
17 O
( O
68 O
% O
) O
during O
5 B
- I
FU I
infusion O
( O
P O
less O
than O
. O
002 O
) O
. O

However O
, O
asymptomatic O
ST O
changes O
( O
greater O
than O
or O
equal O
to O
1 O
mm O
ST O
deviation O
) O
were O
common O
: O
six O
of O
25 O
patients O
( O
24 O
% O
) O
had O
ST O
changes O
before O
5 B
- I
FU I
infusion O
v O
17 O
( O
68 O
% O
) O
during O
5 B
- I
FU I
infusion O
( O
P O
less O
than O
. O
002 O
) O
. O

The O
incidence O
of O
ischemic O
episodes O
per O
patient O
per O
hour O
was O
0 O
. O
05 O
+ O
/ O
- O
0 O
. O
02 O
prior O
to O
5 B
- I
FU I
infusion O
v O
0 O
. O
13 O
+ O
/ O
- O
0 O
. O
03 O
during O
5 B
- I
FU I
infusion O
( O
P O
less O
than O
. O
001 O
) O
; O
the O
duration O
of O
ECG O
changes O
was O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
3 O
minutes O
per O
patient O
per O
hour O
before O
5 B
- I
FU I
v O
1 O
. O
9 O
+ O
/ O
- O
0 O
. O
5 O
minutes O
per O
patient O
per O
hour O
during O
5 B
- I
FU I
( O
P O
less O
than O
. O
01 O
) O
. O

The O
incidence O
of O
ischemic O
episodes O
per O
patient O
per O
hour O
was O
0 O
. O
05 O
+ O
/ O
- O
0 O
. O
02 O
prior O
to O
5 B
- I
FU I
infusion O
v O
0 O
. O
13 O
+ O
/ O
- O
0 O
. O
03 O
during O
5 B
- I
FU I
infusion O
( O
P O
less O
than O
. O
001 O
) O
; O
the O
duration O
of O
ECG O
changes O
was O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
3 O
minutes O
per O
patient O
per O
hour O
before O
5 B
- I
FU I
v O
1 O
. O
9 O
+ O
/ O
- O
0 O
. O
5 O
minutes O
per O
patient O
per O
hour O
during O
5 B
- I
FU I
( O
P O
less O
than O
. O
01 O
) O
. O

The O
incidence O
of O
ischemic O
episodes O
per O
patient O
per O
hour O
was O
0 O
. O
05 O
+ O
/ O
- O
0 O
. O
02 O
prior O
to O
5 B
- I
FU I
infusion O
v O
0 O
. O
13 O
+ O
/ O
- O
0 O
. O
03 O
during O
5 B
- I
FU I
infusion O
( O
P O
less O
than O
. O
001 O
) O
; O
the O
duration O
of O
ECG O
changes O
was O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
3 O
minutes O
per O
patient O
per O
hour O
before O
5 B
- I
FU I
v O
1 O
. O
9 O
+ O
/ O
- O
0 O
. O
5 O
minutes O
per O
patient O
per O
hour O
during O
5 B
- I
FU I
( O
P O
less O
than O
. O
01 O
) O
. O

The O
incidence O
of O
ischemic O
episodes O
per O
patient O
per O
hour O
was O
0 O
. O
05 O
+ O
/ O
- O
0 O
. O
02 O
prior O
to O
5 B
- I
FU I
infusion O
v O
0 O
. O
13 O
+ O
/ O
- O
0 O
. O
03 O
during O
5 B
- I
FU I
infusion O
( O
P O
less O
than O
. O
001 O
) O
; O
the O
duration O
of O
ECG O
changes O
was O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
3 O
minutes O
per O
patient O
per O
hour O
before O
5 B
- I
FU I
v O
1 O
. O
9 O
+ O
/ O
- O
0 O
. O
5 O
minutes O
per O
patient O
per O
hour O
during O
5 B
- I
FU I
( O
P O
less O
than O
. O
01 O
) O
. O

We O
conclude O
that O
5 B
- I
FU I
infusion O
is O
associated O
with O
a O
significant O
increase O
in O
silent O
ST O
segment O
deviation O
suggestive O
of O
ischemia O
, O
particularly O
among O
patients O
with O
coronary O
artery O
disease O
. O

These O
infants O
are O
treated O
with O
two O
injections O
of O
hepatitis O
B O
immune O
globulin O
( O
HBIG O
) O
and O
at O
least O
three O
injections O
of O
plasma O
derived O
hepatitis B
B I
vaccine I
. O

We O
conclude O
that O
the O
analgesic O
action O
of O
opioids O
on O
the O
peripheral O
terminals O
of O
primary O
afferents O
is O
via O
a O
binding O
site O
with O
characteristics O
of O
the O
mu O
- O
opioid O
receptor O
and O
that O
this O
action O
is O
mediated O
by O
inhibition O
of O
the O
cyclic B
adenosine I
monophosphate I
second O
messenger O
system O
. O

The O
highly O
- O
selective O
alpha O
- O
2 O
adrenergic O
agonist O
dexmedetomidine B
( O
D B
- I
MED I
) O
is O
capable O
of O
inducing O
muscle O
flaccidity O
and O
anesthesia O
in O
rats O
and O
dogs O
. O

In O
the O
present O
study O
, O
the O
authors O
determined O
if O
treatment O
with O
D B
- I
MED I
prevents O
the O
muscle O
rigidity O
caused O
by O
high O
- O
dose O
alfentanil B
anesthesia O
in O
the O
rat O
. O

Animals O
( O
n O
= O
42 O
) O
were O
treated O
intraperitoneally O
with O
one O
of O
the O
following O
six O
regimens O
: O
1 O
) O
L O
- O
MED O
( O
the O
inactive O
L O
- O
isomer O
of O
medetomidine B
) O
, O
30 O
micrograms O
/ O
kg O
; O
2 O
) O
D B
- I
MED I
, O
10 O
micrograms O
/ O
kg O
; O
3 O
) O
D B
- I
MED I
, O
30 O
micrograms O
/ O
kg O
; O
4 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O
] O
and O
the O
central O
- O
acting O
alpha O
- O
2 O
antagonist O
, O
idazoxan B
[ O
10 O
mg O
/ O
kg O
] O
; O
5 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O

Animals O
( O
n O
= O
42 O
) O
were O
treated O
intraperitoneally O
with O
one O
of O
the O
following O
six O
regimens O
: O
1 O
) O
L O
- O
MED O
( O
the O
inactive O
L O
- O
isomer O
of O
medetomidine B
) O
, O
30 O
micrograms O
/ O
kg O
; O
2 O
) O
D B
- I
MED I
, O
10 O
micrograms O
/ O
kg O
; O
3 O
) O
D B
- I
MED I
, O
30 O
micrograms O
/ O
kg O
; O
4 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O
] O
and O
the O
central O
- O
acting O
alpha O
- O
2 O
antagonist O
, O
idazoxan B
[ O
10 O
mg O
/ O
kg O
] O
; O
5 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O

Animals O
( O
n O
= O
42 O
) O
were O
treated O
intraperitoneally O
with O
one O
of O
the O
following O
six O
regimens O
: O
1 O
) O
L O
- O
MED O
( O
the O
inactive O
L O
- O
isomer O
of O
medetomidine B
) O
, O
30 O
micrograms O
/ O
kg O
; O
2 O
) O
D B
- I
MED I
, O
10 O
micrograms O
/ O
kg O
; O
3 O
) O
D B
- I
MED I
, O
30 O
micrograms O
/ O
kg O
; O
4 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O
] O
and O
the O
central O
- O
acting O
alpha O
- O
2 O
antagonist O
, O
idazoxan B
[ O
10 O
mg O
/ O
kg O
] O
; O
5 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O

Animals O
( O
n O
= O
42 O
) O
were O
treated O
intraperitoneally O
with O
one O
of O
the O
following O
six O
regimens O
: O
1 O
) O
L O
- O
MED O
( O
the O
inactive O
L O
- O
isomer O
of O
medetomidine B
) O
, O
30 O
micrograms O
/ O
kg O
; O
2 O
) O
D B
- I
MED I
, O
10 O
micrograms O
/ O
kg O
; O
3 O
) O
D B
- I
MED I
, O
30 O
micrograms O
/ O
kg O
; O
4 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O
] O
and O
the O
central O
- O
acting O
alpha O
- O
2 O
antagonist O
, O
idazoxan B
[ O
10 O
mg O
/ O
kg O
] O
; O
5 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O

] O
and O
the O
peripheral O
- O
acting O
alpha O
- O
2 O
antagonist O
DG B
- I
5128 I
[ O
10 O
mg O
/ O
kg O
] O
, O
or O
; O
6 O
) O
saline O
. O

In O
contrast O
, O
D B
- I
MED I
prevented O
alfentanil B
- O
induced O
muscle O
rigidity O
in O
a O
dose O
- O
dependent O
fashion O
. O

The O
small O
EMG O
values O
obtained O
in O
the O
high O
- O
dose O
D B
- I
MED I
group O
were O
comparable O
with O
those O
recorded O
in O
earlier O
studies O
from O
control O
animals O
not O
given O
any O
opiate O
. O

The O
high O
- O
dose O
D B
- I
MED I
animals O
were O
flaccid O
, O
akinetic O
, O
and O
lacked O
a O
startle O
response O
during O
the O
entire O
experimental O
period O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Reversal O
of O
neuroleptic O
- O
induced O
catalepsy O
by O
novel O
aryl B
- I
piperazine I
anxiolytic O
drugs O
. O

A O
series O
of O
aryl B
- I
piperazine I
analogues O
of O
buspirone B
and O
other O
5 B
- I
hydroxytryptaminergic I
agonists I
were O
tested O
for O
their O
ability O
to O
reverse O
haloperidol B
induced O
catalepsy O
. O

Those O
drugs O
with O
strong O
affinity O
for O
5 B
- I
hydroxytryptamine1a I
receptors O
were O
able O
to O
reverse O
catalepsy O
. O

Drugs O
with O
affinity O
for O
other O
5 B
- I
HT I
receptors O
or O
weak O
affinity O
were O
ineffective O
. O

However O
, O
inhibition O
of O
postsynaptic O
5 B
- I
HT I
receptors O
neither O
inhibited O
nor O
potentiated O
reversal O
of O
catalepsy O
and O
leaves O
open O
the O
question O
as O
to O
the O
site O
or O
mechanism O
for O
this O
effect O
. O

A O
strong O
association O
has O
been O
found O
between O
nephritis O
and O
dermatitis O
due O
to O
Tiopronin B
( O
a O
D B
- I
Penicillamine I
like O
compound O
) O
and O
class O
I O
antigens O
B35 O
- O
Cw4 O
, O
and O
between O
dermatitis O
due O
to O
gold B
thiosulphate B
and O
B35 O
. O

Following O
unilateral O
6 B
- I
OHDA I
induced O
SN O
lesion O
, O
a O
transient O
period O
of O
contralateral O
rotation O
has O
been O
reported O
to O
precede O
the O
predominant O
ipsilateral O
circling O
. O

Antagonism O
of O
diazepam B
- O
induced O
sedative O
effects O
by O
Ro15 B
- I
1788 I
in O
patients O
after O
surgery O
under O
lumbar O
epidural O
block O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
of O
Ro15 B
- I
1788 I
and O
a O
placebo O
in O
reversing O
diazepam B
- O
induced O
effects O
after O
surgery O
under O
epidural O
block O
, O
and O
to O
evaluate O
the O
local O
tolerance O
and O
general O
safety O
of O
Ro15 B
- I
1788 I
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
of O
Ro15 B
- I
1788 I
and O
a O
placebo O
in O
reversing O
diazepam B
- O
induced O
effects O
after O
surgery O
under O
epidural O
block O
, O
and O
to O
evaluate O
the O
local O
tolerance O
and O
general O
safety O
of O
Ro15 B
- I
1788 I
. O

Antagonism O
of O
diazepam B
- O
induced O
effects O
by O
Ro15 B
- I
1788 I
was O
investigated O
postoperatively O
in O
a O
double O
- O
blind O
placebo O
- O
controlled O
trial O
. O

The O
Ro15 B
- I
1788 I
group O
showed O
a O
significant O
improvement O
in O
the O
performance O
test O
up O
to O
120 O
min O
after O
administration O
of O
the O
drug O
. O

Acute O
experimental O
models O
of O
renal O
damage O
to O
the O
proximal O
tubular O
, O
glomerular O
, O
and O
papillary O
regions O
of O
the O
rat O
were O
produced O
by O
administration O
of O
hexachloro B
- I
1 I
: I
3 I
- I
butadiene I
( O
HCBD B
) O
, O
puromycin B
aminonucleoside I
( O
PAN B
) O
, O
and O
2 B
- I
bromoethylamine I
( O
BEA B
) O
, O
respectively O
. O

Cardiac O
toxicity O
of O
5 B
- I
fluorouracil I
. O

We O
report O
a O
case O
of O
a O
patient O
with O
colon O
carcinoma O
and O
liver O
metastasis O
who O
presented O
chest O
pain O
after O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
administration O
. O

We O
report O
a O
case O
of O
a O
patient O
with O
colon O
carcinoma O
and O
liver O
metastasis O
who O
presented O
chest O
pain O
after O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
administration O
. O

These O
data O
suggest O
that O
coronary O
spasm O
may O
be O
the O
cause O
of O
cardiotoxicity O
due O
to O
5 B
- I
FU I
, O
and O
that O
calcium B
antagonists O
may O
probably O
be O
used O
in O
the O
prevention O
or O
treatment O
of O
5 B
- I
FU I
cardiotoxicity O
. O

These O
data O
suggest O
that O
coronary O
spasm O
may O
be O
the O
cause O
of O
cardiotoxicity O
due O
to O
5 B
- I
FU I
, O
and O
that O
calcium B
antagonists O
may O
probably O
be O
used O
in O
the O
prevention O
or O
treatment O
of O
5 B
- I
FU I
cardiotoxicity O
. O

Increasing O
the O
brain O
serotonin B
levels O
by O
the O
administration O
of O
5 B
- I
hydroxytryptophan I
( O
80 O
- O
160 O
mg O
/ O
kg O
) O
in O
combination O
with O
a O
peripheral O
decarboxylase O
inhibitor O
resulted O
in O
an O
inhibition O
of O
the O
muscimol B
effect O
. O

However O
, O
in O
a O
similar O
experiment O
l B
- I
dopa I
( O
80 O
- O
160 O
mg O
/ O
kg O
) O
was O
without O
effect O
. O

In O
doses O
of O
3 O
- O
10 O
mg O
/ O
kg O
, O
the O
serotonin B
receptor O
agonist O
MK B
- I
212 I
caused O
a O
dose O
- O
dependent O
blockade O
of O
the O
response O
of O
muscimol B
. O

Considering O
the O
fact O
that O
5 B
- I
HTP I
and O
the O
benzodiazepines B
have O
been O
found O
to O
be O
beneficial O
in O
the O
management O
of O
clinical O
myoclonus O
, O
the O
muscimol B
- O
induced O
myoclonus O
seems O
to O
be O
a O
satisfactory O
animal O
model O
that O
may O
prove O
useful O
for O
the O
development O
of O
new O
drug O
treatments O
for O
this O
condition O
. O

Our O
present O
study O
indicated O
the O
possible O
value O
of O
MK B
- I
212 I
and O
( O
- O
) O
- O
baclofen B
in O
the O
management O
of O
clinical O
myoclonus O
. O

The O
toxicity O
of O
Renografin B
76 I
% I
was O
compared O
with O
that O
of O
Hypaque B
76 I
% I
by O
selective O
injection O
of O
each O
into O
the O
right O
coronary O
artery O
of O
dogs O
. O

The O
toxicity O
of O
Renografin B
76 I
% I
was O
compared O
with O
that O
of O
Hypaque B
76 I
% I
by O
selective O
injection O
of O
each O
into O
the O
right O
coronary O
artery O
of O
dogs O
. O

Renografin B
contains O
the O
chelating O
agents O
sodium B
citrate I
and O
disodium B
edetate I
, O
while O
Hypaque B
contains O
calcium B
disodium I
edetate I
and O
no O
sodium B
citrate I
. O

Hepatic O
veno O
- O
occlusive O
disease O
caused O
by O
6 B
- I
thioguanine I
. O

Clinically O
reversible O
veno O
- O
occlusive O
disease O
of O
the O
liver O
developed O
in O
a O
23 O
- O
year O
- O
old O
man O
with O
acute O
lymphocytic O
leukemia O
after O
10 O
months O
of O
maintenance O
therapy O
with O
6 B
- I
thioguanine I
. O

This O
case O
presented O
a O
unique O
opportunity O
to O
observe O
the O
histologic O
features O
of O
clinically O
reversible O
hepatic O
veno O
- O
occlusive O
disease O
over O
time O
, O
and O
may O
be O
the O
first O
case O
of O
veno O
- O
occlusive O
related O
solely O
to O
6 B
- I
thioguanine I
. O

Reversal O
of O
ammonia B
coma O
in O
rats O
by O
L B
- I
dopa I
: O
a O
peripheral O
effect O
. O

This O
coma O
was O
prevented O
with O
1 O
. O
68 O
mmol O
L B
- I
dopa I
given O
by O
gastric O
intubation O
15 O
minutes O
before O
the O
ammonium B
salt I
injection O
. O

The O
effect O
of O
L B
- I
dopa I
was O
correlated O
with O
a O
decrease O
in O
blood O
and O
brain O
ammonia B
, O
an O
increase O
in O
brain O
dopamine B
, O
and O
an O
increase O
in O
renal O
excretion O
of O
ammonia B
and O
urea B
. O

Bilateral O
nephrectomy O
eliminated O
the O
beneficial O
effect O
of O
L B
- I
dopa I
on O
blood O
and O
brain O
ammonia B
and O
the O
ammonia B
coma O
was O
not O
prevented O
. O

Thus O
, O
the O
reduction O
in O
blood O
and O
brain O
ammonia B
and O
the O
prevention O
of O
ammonia B
coma O
after O
L B
- I
dopa I
, O
can O
be O
accounted O
for O
by O
the O
peripheral O
effect O
of O
dopamine B
on O
renal O
function O
rather O
than O
its O
central O
action O
. O

These O
results O
provide O
a O
reasonable O
explanation O
for O
the O
beneficial O
effects O
observed O
in O
some O
encephalopathic O
patients O
receiving O
L B
- I
dopa I
. O

PURPOSE O
: O
Treatment O
of O
neuroblastoma O
cell O
lines O
with O
13 B
- I
cis I
- I
retinoic I
acid I
( O
cis B
- I
RA I
) O
can O
cause O
sustained O
inhibition O
of O
proliferation O
. O

Since O
cis B
- I
RA I
has O
demonstrated O
clinical O
responses O
in O
neuroblastoma O
patients O
, O
it O
may O
be O
effective O
in O
preventing O
relapse O
after O
cytotoxic O
therapy O
. O

This O
phase O
I O
trial O
was O
designed O
to O
determine O
the O
maximal O
- O
tolerated O
dosage O
( O
MTD O
) O
, O
toxicities O
, O
and O
pharmacokinetics O
of O
cis B
- I
RA I
administered O
on O
an O
intermittent O
schedule O
in O
children O
with O
neuroblastoma O
following O
bone O
marrow O
transplantation O
( O
BMT O
) O
. O

PATIENTS O
AND O
METHODS O
: O
Fifty O
- O
one O
assessable O
patients O
, O
2 O
to O
12 O
years O
of O
age O
, O
were O
treated O
with O
oral O
cis B
- I
RA I
administered O
in O
two O
equally O
divided O
doses O
daily O
for O
2 O
weeks O
, O
followed O
by O
a O
2 O
- O
week O
rest O
period O
, O
for O
up O
to O
12 O
courses O
. O

RESULTS O
: O
The O
MTD O
of O
cis B
- I
RA I
was O
160 O
mg O
/ O
m2 O
/ O
d O
. O

All O
toxicities O
resolved O
after O
cis B
- I
RA I
was O
discontinued O
. O

CONCLUSION O
: O
The O
MTD O
of O
cis B
- I
RA I
given O
on O
this O
intermittent O
schedule O
was O
160 O
mg O
/ O
m2 O
/ O
d O
. O

The O
DLT O
included O
hypercalcemia O
, O
and O
may O
be O
predicted O
by O
serum O
cis B
- I
RA I
levels O
. O

Monitoring O
of O
serum O
calcium B
and O
cis B
- I
RA I
levels O
is O
indicated O
in O
future O
trials O
. O

Laboratory O
variables O
of O
renal O
function O
[ O
serum O
creatinine B
, O
blood B
urea I
nitrogen I
( O
BUN B
) O
and O
electrolytes O
] O
were O
evaluated O
before O
initiation O
of O
therapy O
and O
every O
2 O
days O
, O
until O
termination O
of O
the O
study O
( O
a O
period O
of O
at O
least O
6 O
days O
) O
. O

The O
safety O
and O
efficacy O
of O
combination O
N B
- I
butyl I
- I
deoxynojirimycin I
( O
SC B
- I
48334 I
) O
and O
zidovudine B
in O
patients O
with O
HIV O
- O
1 O
infection O
and O
200 O
- O
500 O
CD4 O
cells O
/ O
mm3 O
. O

We O
conducted O
a O
double O
- O
blind O
, O
randomized O
phase O
II O
study O
to O
evaluate O
the O
safety O
and O
activity O
of O
combination O
therapy O
with O
N B
- I
butyl I
- I
deoxynojirimycin I
( O
SC B
- I
48334 I
) O
( O
an O
alpha O
- O
glucosidase O
I O
inhibitor O
) O
and O
zidovudine B
versus O
zidovudine B
alone O
. O

Patients O
with O
200 O
to O
500 O
CD4 O
cells O
/ O
mm3 O
who O
tolerated O
< O
or O
= O
12 O
weeks O
of O
prior O
zidovudine B
therapy O
received O
SC B
- I
48334 I
( O
1000 O
mg O
every O
8 O
h O
) O
and O
zidovudine B
( O
100 O
mg O
every O
8 O
h O
) O
or O
zidovudine B
and O
placebo O
. O

The O
mean O
SC B
- I
48334 I
steady O
- O
state O
trough O
level O
( O
4 O
. O
04 O
+ O
/ O
- O
0 O
. O
99 O
micrograms O
/ O
ml O
) O
was O
below O
the O
in O
vitro O
inhibitory O
concentration O
for O
human O
immunodeficiency O
virus O
( O
HIV O
) O
. O

The O
long O
- O
term O
use O
of O
nondepolarizing B
neuromuscular I
blocking I
agents I
( O
ND B
- I
NMBA I
) O
has O
recently O
been O
implicated O
as O
a O
cause O
of O
prolonged O
muscle O
weakness O
, O
although O
the O
site O
of O
the O
lesion O
and O
the O
predisposing O
factors O
have O
been O
unclear O
. O

We O
report O
3 O
patients O
( O
age O
37 O
- O
52 O
years O
) O
with O
acute O
respiratory O
insufficiency O
who O
developed O
prolonged O
weakness O
following O
the O
discontinuation O
of O
ND B
- I
NMBAs I
. O

The O
weakness O
in O
these O
patients O
is O
due O
to O
pathology O
at O
both O
the O
neuromuscular O
junction O
( O
most O
likely O
due O
to O
ND B
- I
NMBA I
) O
and O
muscle O
( O
most O
likely O
due O
to O
corticosteroids B
) O
. O

Moreover O
, O
KF17837 B
( O
0 O
. O
625 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
potentiated O
the O
anticataleptic O
effects O
of O
a O
subthreshold O
dose O
of O
L B
- I
3 I
, I
4 I
- I
dihydroxyphenylalanine I
( O
L B
- I
DOPA I
; O
25 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
plus O
benserazide B
( O
6 O
. O
25 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

Effect O
of O
nondopaminergic O
drugs O
on O
L B
- I
dopa I
- O
induced O
dyskinesias O
in O
MPTP B
- O
treated O
monkeys O
. O

A O
series O
of O
agents O
acting O
primarily O
on O
neurotransmitters O
other O
than O
dopamine B
were O
then O
tested O
in O
combination O
with O
L B
- I
DOPA I
to O
see O
if O
the O
dyskinetic O
movements O
would O
be O
modified O
. O

Several O
drugs O
, O
including O
clonidine B
, O
physostigmine B
, O
methysergide B
, O
5 B
- I
MDOT I
, O
propranolol B
, O
and O
MK B
- I
801 I
, O
markedly O
reduced O
the O
dyskinetic O
movements O
but O
at O
the O
cost O
of O
a O
return O
of O
parkinsonian O
symptomatology O
. O

Several O
drugs O
, O
including O
clonidine B
, O
physostigmine B
, O
methysergide B
, O
5 B
- I
MDOT I
, O
propranolol B
, O
and O
MK B
- I
801 I
, O
markedly O
reduced O
the O
dyskinetic O
movements O
but O
at O
the O
cost O
of O
a O
return O
of O
parkinsonian O
symptomatology O
. O

A O
67 O
- O
year O
- O
old O
woman O
with O
rheumatoid O
arthritis O
presented O
rapidly O
progressive O
glomerulonephritis O
( O
RPGN O
) O
after O
5 O
months O
of O
D B
- I
penicillamine I
( O
250 O
mg O
/ O
day O
) O
treatment O
. O

This O
new O
case O
of O
RPGN O
in O
the O
course O
of O
D B
- I
penicillamine I
treatment O
emphasizes O
the O
need O
for O
frequent O
monitoring O
of O
renal O
function O
and O
evaluation O
of O
urinary O
sediment O
and O
proteinuria O
in O
these O
patients O
. O

The O
prompt O
discontinuation O
of O
D B
- I
penicillamine I
and O
vigorous O
treatment O
measures O
could O
allow O
for O
a O
good O
prognosis O
as O
in O
this O
case O
. O

A O
case O
of O
polymyositis O
in O
a O
patient O
with O
primary O
biliary O
cirrhosis O
treated O
with O
D B
- I
penicillamine I
. O

Although O
D B
- I
penicillamine I
has O
been O
used O
for O
many O
rheumatologic O
diseases O
, O
toxicity O
limits O
its O
usefulness O
in O
many O
patients O
. O

Polymyositis O
/ O
dermatomyositis O
can O
develop O
as O
one O
of O
the O
autoimmune O
complications O
of O
D B
- I
penicillamine I
treatment O
, O
but O
its O
exact O
pathogenesis O
remains O
unclear O
. O

We O
report O
a O
patient O
with O
primary O
biliary O
cirrhosis O
, O
who O
developed O
polymyositis O
while O
receiving O
D B
- I
penicillamine I
therapy O
. O

Patients O
receiving O
D B
- I
penicillamine I
therapy O
should O
be O
followed O
carefully O
for O
the O
development O
of O
autoimmune O
complications O
like O
polymyositis O
/ O
dermatomyositis O
. O

BMT O
was O
used O
to O
treat O
severe O
aplastic O
anemia O
which O
was O
caused O
by O
gold B
in O
one O
case O
and O
D B
- I
penicillamine I
in O
the O
other O
. O

OBJECTIVE O
: O
To O
test O
the O
hypothesis O
that O
, O
in O
lifetime O
captopril B
- O
treated O
spontaneously O
hypertensive O
rats O
( O
SHR O
) O
, O
the O
sympathetic O
nervous O
system O
contributes O
importantly O
to O
the O
hypertensive O
effect O
of O
dietary B
sodium I
chloride I
supplementation O
. O

Intravenous O
infusion O
of O
the O
ganglionic O
blocker O
hexamethonium B
resulted O
in O
a O
rapid O
decline O
in O
MAP O
that O
eliminated O
the O
dietary B
sodium I
chloride I
- O
induced O
increase O
in O
MAP O
in O
both O
groups O
. O

Recently O
, O
we O
demonstrated O
the O
hepatoprotective O
effects O
of O
nicotinic B
acid I
amide I
, O
a O
selective O
inhibitor O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
; O
EC O
2 O
. O
4 O
. O
2 O
. O
30 O
) O
on O
mice O
suffering O
from O
acetaminophen B
( O
AAP B
) O
- O
hepatitis O
, O
suggesting O
that O
the O
AAP B
- O
induced O
liver O
injury O
involves O
a O
step O
which O
depends O
on O
adenoribosylation O
. O

While O
AAP B
caused O
a O
117 O
- O
fold O
elevation O
of O
serum O
transaminase O
activities O
in O
mice O
kept O
on O
a O
standard O
laboratory O
diet O
, O
which O
was O
significantly O
exacerbated O
by O
ethanol B
and O
inhibited O
by O
nicotinic B
acid I
amide I
( O
NAA B
) O
, O
adverse O
effects O
were O
noted O
in O
animals O
fed O
a O
diet O
free O
of O
precursors O
of O
NAD B
. O

Effect O
of O
calcium B
chloride I
and O
4 B
- I
aminopyridine I
therapy O
on O
desipramine B
toxicity O
in O
rats O
. O

CaCl2 B
and O
4 B
- I
aminopyridine I
. O

In O
a O
second O
experiment O
, O
rats O
received O
tricyclic O
antidepressant O
desipramine B
IP O
followed O
in O
15 O
min O
by O
4 B
- I
aminopyridine I
or O
saline O
. O

CaCl2 B
and O
4 B
- I
aminopyridine I
failed O
to O
improve O
blood O
pressure O
. O

CONCLUSION O
: O
The O
administration O
of O
CaCl2 B
or O
4 B
- I
aminopyridine I
did O
not O
reverse O
tricyclic O
antidepressant O
- O
induced O
hypotension O
in O
rats O
. O

In O
addition O
, O
carteolol B
did O
not O
evoke O
5 O
- O
HT1A O
receptor O
- O
stimulating O
behavioral O
signs O
such O
as O
flat O
body O
posture O
and O
forepaw O
treading O
and O
did O
not O
inhibit O
5 B
- I
hydroxytryptophan I
- O
induced O
head O
twitch O
in O
rats O
. O

The O
results O
demonstrated O
that O
17beta B
- I
estradiol I
( O
E2 B
) O
induces O
neovascularization O
, O
as O
well O
as O
the O
growth O
and O
enlargement O
of O
blood O
vessels O
after O
7 O
days O
of O
exposure O
. O

Effects O
of O
NIK B
- I
247 I
on O
cholinesterase O
and O
scopolamine B
- O
induced O
amnesia O
. O

The O
effects O
of O
NIK B
- I
247 I
on O
cholinesterase O
, O
scopolamine B
- O
induced O
amnesia O
and O
spontaneous O
movement O
were O
examined O
and O
compared O
with O
those O
of O
the O
well O
- O
known O
cholinesterase O
inhibitors O
tacrine B
and O
E B
- I
2020 I
. O

The O
effects O
of O
NIK B
- I
247 I
on O
cholinesterase O
, O
scopolamine B
- O
induced O
amnesia O
and O
spontaneous O
movement O
were O
examined O
and O
compared O
with O
those O
of O
the O
well O
- O
known O
cholinesterase O
inhibitors O
tacrine B
and O
E B
- I
2020 I
. O

NIK B
- I
247 I
, O
tacrine B
and O
E B
- I
2020 I
all O
strongly O
inhibited O
acetylcholinesterase O
( O
AChE O
) O
in O
human O
red O
blood O
cells O
( O
IC50s O
= O
1 O
. O
0 O
x O
10 O
( O
- O
6 O
) O
, O
2 O
. O
9 O
x O
10 O
( O
- O
7 O
) O
and O
3 O
. O
7 O
x O
10 O
( O
- O
8 O
) O
M O
, O
respectively O
) O
. O

NIK B
- I
247 I
, O
tacrine B
and O
E B
- I
2020 I
all O
strongly O
inhibited O
acetylcholinesterase O
( O
AChE O
) O
in O
human O
red O
blood O
cells O
( O
IC50s O
= O
1 O
. O
0 O
x O
10 O
( O
- O
6 O
) O
, O
2 O
. O
9 O
x O
10 O
( O
- O
7 O
) O
and O
3 O
. O
7 O
x O
10 O
( O
- O
8 O
) O
M O
, O
respectively O
) O
. O

In O
addition O
, O
NIK B
- I
247 I
and O
tacrine B
, O
but O
not O
E B
- I
2020 I
, O
strongly O
inhibited O
butyrylcholinestrase O
( O
BuChE O
) O
in O
human O
serum O
. O

In O
addition O
, O
NIK B
- I
247 I
and O
tacrine B
, O
but O
not O
E B
- I
2020 I
, O
strongly O
inhibited O
butyrylcholinestrase O
( O
BuChE O
) O
in O
human O
serum O
. O

Moreover O
, O
the O
inhibitory O
effect O
of O
NIK B
- I
247 I
on O
AChE O
was O
reversible O
. O

These O
findings O
suggest O
that O
NIK B
- I
247 I
at O
a O
low O
dose O
( O
0 O
. O
1 O
- O
1 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
improves O
scopolamine B
- O
induced O
amnesia O
but O
does O
not O
affect O
spontaneous O
movement O
. O

The O
findings O
suggest O
that O
NIK B
- I
247 I
may O
be O
a O
useful O
drug O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
. O

Potential O
therapeutic O
use O
of O
the O
selective O
dopamine B
D1 O
receptor O
agonist O
, O
A B
- I
86929 I
: O
an O
acute O
study O
in O
parkinsonian O
levodopa B
- O
primed O
monkeys O
. O

The O
therapeutic O
use O
of O
selective O
DA B
D1 O
receptor O
agonists O
such O
as O
SKF B
- I
82958 I
( O
6 B
- I
chloro I
- I
7 I
, I
8 I
- I
dihydroxy I
- I
3 I
- I
allyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzaze I
pine I
hydrobromide I
) O
and O
A B
- I
77636 I
( O
[ B
1R I
, I
3S I
] I
3 I
- I
[ I
1 I
' I
- I
admantyl I
] I
- I
1 I
- I
aminomethyl I
- I
3 I
, I
4 I
- I
dihydro I
- I
5 I
, I
6 I
- I

The O
therapeutic O
use O
of O
selective O
DA B
D1 O
receptor O
agonists O
such O
as O
SKF B
- I
82958 I
( O
6 B
- I
chloro I
- I
7 I
, I
8 I
- I
dihydroxy I
- I
3 I
- I
allyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzaze I
pine I
hydrobromide I
) O
and O
A B
- I
77636 I
( O
[ B
1R I
, I
3S I
] I
3 I
- I
[ I
1 I
' I
- I
admantyl I
] I
- I
1 I
- I
aminomethyl I
- I
3 I
, I
4 I
- I
dihydro I
- I
5 I
, I
6 I
- I

dihydroxy I
- I
1H I
- I
2 I
- I
benzo I
pyran I
hydrochloride I
) O
seems O
limited O
because O
of O
their O
duration O
of O
action O
, O
which O
is O
too O
short O
for O
SKF B
- I
82958 I
( O
< O
1 O
hr O
) O
and O
too O
long O
for O
A B
- I
77636 I
( O
> O
20 O
hr O
, O
leading O
to O
behavioral O
tolerance O
) O
. O

We O
therefore O
conducted O
the O
present O
acute O
dose O
- O
response O
study O
in O
four O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
- O
exposed O
cynomolgus O
monkeys O
primed O
to O
exhibit O
levodopa B
- O
induced O
dyskinesias O
to O
evaluate O
the O
locomotor O
and O
dyskinetic O
effects O
on O
challenge O
with O
four O
doses O
( O
from O
0 O
. O
03 O
to O
1 O
. O
0 O
mg O
/ O
kg O
) O
of O
A B
- I
86929 I
( O
[ B
- I
] I
- I
[ I
5aR I
, I
11bS I
] I
- I
4 I
, I
5 I
, I
5a I
, I
6 I
, I

Levodopa B
and O
the O
DA B
D2 O
- O
like O
receptor O
agonist O
, O
LY B
- I
171555 I
( O
[ B
4aR I
- I
trans I
] I
- I
4 I
, I
4a I
, I
5 I
, I
6 I
, I
7 I
, I
8 I
, I
8a I
, I
9 I
- I
o I
- I
dihydro I
- I
5n I
- I
propyl I
- I
2H I
- I
pyrazo I
lo I
- I
3 I
- I
4 I
- I
quinoline I
hydrochloride I
) O
were O
also O
used O
for O
comparison O
. O

Acute O
administration O
of O
A B
- I
86929 I
was O
as O
efficacious O
in O
alleviating O
MPTP B
- O
induced O
parkinsonism O
as O
levodopa B
and O
LY B
- I
171555 I
, O
but O
was O
less O
likely O
to O
reproduce O
the O
levodopa B
- O
induced O
dyskinesias O
in O
these O
animals O
than O
with O
either O
LY B
- I
171555 I
or O
subsequent O
challenge O
of O
levodopa B
. O

Acute O
administration O
of O
A B
- I
86929 I
was O
as O
efficacious O
in O
alleviating O
MPTP B
- O
induced O
parkinsonism O
as O
levodopa B
and O
LY B
- I
171555 I
, O
but O
was O
less O
likely O
to O
reproduce O
the O
levodopa B
- O
induced O
dyskinesias O
in O
these O
animals O
than O
with O
either O
LY B
- I
171555 I
or O
subsequent O
challenge O
of O
levodopa B
. O

Acute O
administration O
of O
A B
- I
86929 I
was O
as O
efficacious O
in O
alleviating O
MPTP B
- O
induced O
parkinsonism O
as O
levodopa B
and O
LY B
- I
171555 I
, O
but O
was O
less O
likely O
to O
reproduce O
the O
levodopa B
- O
induced O
dyskinesias O
in O
these O
animals O
than O
with O
either O
LY B
- I
171555 I
or O
subsequent O
challenge O
of O
levodopa B
. O

Potent O
DA B
D1 O
receptor O
agents O
with O
an O
intermediate O
duration O
of O
efficacy O
such O
as O
A B
- I
86929 I
( O
approximately O
4 O
hr O
at O
higher O
doses O
tested O
) O
are O
potential O
therapeutic O
tools O
in O
PD O
and O
merit O
further O
attention O
. O

Four O
patients O
with O
rheumatoid O
arthritis O
developed O
heavy O
proteinuria O
after O
five O
to O
12 O
months O
of O
treatment O
with O
D B
- I
penicillamine I
. O

Cortical O
motor O
overactivation O
in O
parkinsonian O
patients O
with O
L B
- I
dopa I
- O
induced O
peak O
- O
dose O
dyskinesia O
. O

We O
have O
studied O
the O
regional O
cerebral O
blood O
flow O
( O
rCBF O
) O
changes O
induced O
by O
the O
execution O
of O
a O
finger O
- O
to O
- O
thumb O
opposition O
motor O
task O
in O
the O
supplementary O
and O
primary O
motor O
cortex O
of O
two O
groups O
of O
parkinsonian O
patients O
on O
L B
- I
dopa I
medication O
, O
the O
first O
one O
without O
L B
- I
dopa I
induced O
dyskinesia O
( O
n O
= O
23 O
) O
and O
the O
other O
with O
moderate O
peak O
- O
dose O
dyskinesia O
( O
n O
= O
15 O
) O
, O
and O
of O
a O
group O
of O
14 O
normal O
subjects O
. O

We O
have O
studied O
the O
regional O
cerebral O
blood O
flow O
( O
rCBF O
) O
changes O
induced O
by O
the O
execution O
of O
a O
finger O
- O
to O
- O
thumb O
opposition O
motor O
task O
in O
the O
supplementary O
and O
primary O
motor O
cortex O
of O
two O
groups O
of O
parkinsonian O
patients O
on O
L B
- I
dopa I
medication O
, O
the O
first O
one O
without O
L B
- I
dopa I
induced O
dyskinesia O
( O
n O
= O
23 O
) O
and O
the O
other O
with O
moderate O
peak O
- O
dose O
dyskinesia O
( O
n O
= O
15 O
) O
, O
and O
of O
a O
group O
of O
14 O
normal O
subjects O
. O

These O
results O
are O
compatible O
with O
the O
hypothesis O
that O
an O
hyperkinetic O
abnormal O
involuntary O
movement O
, O
like O
L B
- I
dopa I
- O
induced O
peak O
dose O
dyskinesia O
, O
is O
due O
to O
a O
disinhibition O
of O
the O
primary O
and O
associated O
motor O
cortex O
secondary O
to O
an O
excessive O
outflow O
of O
the O
pallidothalamocortical O
motor O
loop O
. O

Chronic O
effects O
of O
a O
novel O
synthetic O
anthracycline B
derivative O
( O
SM B
- I
5887 I
) O
on O
normal O
heart O
and O
doxorubicin B
- O
induced O
cardiomyopathy O
in O
beagle O
dogs O
. O

This O
study O
was O
designed O
to O
investigate O
the O
chronic O
cardiotoxic O
potential O
of O
SM B
- I
5887 I
and O
a O
possible O
deteriorating O
effect O
of O
SM B
- I
5887 I
on O
low O
- O
grade O
cardiotoxicity O
pre O
- O
induced O
by O
doxorubicin B
in O
beagle O
dogs O
. O

This O
study O
was O
designed O
to O
investigate O
the O
chronic O
cardiotoxic O
potential O
of O
SM B
- I
5887 I
and O
a O
possible O
deteriorating O
effect O
of O
SM B
- I
5887 I
on O
low O
- O
grade O
cardiotoxicity O
pre O
- O
induced O
by O
doxorubicin B
in O
beagle O
dogs O
. O

In O
the O
chronic O
treatment O
, O
beagle O
dogs O
of O
each O
sex O
were O
given O
intravenously O
once O
every O
3 O
weeks O
, O
either O
a O
sublethal O
dose O
of O
doxorubicin B
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
or O
SM B
- I
5887 I
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
. O

Animals O
which O
received O
over O
six O
courses O
of O
doxorubicin B
demonstrated O
the O
electrocardiogram O
( O
ECG O
) O
changes O
, O
decrease O
of O
blood O
pressure O
and O
high O
- O
grade O
histopathological O
cardiomyopathy O
, O
while O
animals O
which O
were O
terminally O
sacrificed O
after O
the O
SM B
- I
5887 I
administration O
did O
not O
show O
any O
changes O
in O
ECG O
, O
blood O
pressure O
and O
histopathological O
examinations O
. O

To O
examine O
a O
possibly O
deteriorating O
cardiotoxic O
effect O
of O
SM B
- I
5887 I
, O
low O
- O
grade O
cardiomyopathy O
was O
induced O
in O
dogs O
by O
four O
courses O
of O
doxorubicin B
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
. O

Nine O
weeks O
after O
pre O
- O
treatment O
, O
dogs O
were O
given O
four O
courses O
of O
either O
doxorubicin B
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
or O
SM B
- I
5887 I
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
once O
every O
3 O
weeks O
. O

On O
the O
contrary O
, O
the O
SM B
- I
5887 I
treatment O
did O
not O
progress O
the O
grade O
of O
cardiomyopathy O
. O

In O
conclusion O
, O
SM B
- I
5887 I
does O
not O
have O
any O
potential O
of O
chronic O
cardiotoxicity O
and O
deteriorating O
effect O
on O
doxorubicin B
- O
induced O
cardiotoxicity O
in O
dogs O
. O

